Clinical, pathologic, and genetic features of Wilms tumors with WTX gene mutation.

Clinical and pathologic features of patients with WTX-mutated Wilms tumor (WT) have not been studied in detail. We characterize the clinical and pathologic findings in WT with WTX abnormalities and provide comparison with WT without WTX mutation. Clinical, gross, and microscopic features in 35 patients with WT were examined. Karyotype was examined in a subset of cases. All cases had been previously analyzed for WTX, WT1, and CTNNB1 aberrations via array comparative genomic hybridization; OncoMap 4 high throughput genotyping was performed on 18 cases. Eleven tumors had WTX abnormality. No significant differences were identified between patients with mutated versus nonmutated WTX with respect to gender (45 versus 33% male), age (mean 3.9 versus 4.1 years), tumor size (mean 12.7 versus 12.8 cm), anaplasia (9 versus 12%), rhabdomyoblastic differentiation (18 versus 8%), cartilage differentiation (9 versus 4%), mucinous epithelial differentiation (9 versus 4%), nephrogenic rests (28 versus 21%), or relapse rate (11 versus 25%). Mutations in KRAS, MYC, and PIK3R1 were restricted to WTX-mutated WT, mutations in AKT, CKDN2A, EFGR, HRAS, MET, and RET were restricted to WT without WTX mutation, and mutations in BRAF, CTTNB1, NRAS, PDGFRA, and STK11 were seen in both groups. Our study revealed no clinical or pathologic distinctions between WT with and without WTX abnormality. This similarity lends support to the concept of a common tumorigenic pathway between WT with aberrant WTX and those without.

[1]  D. Sahu,et al.  Retrospective analysis of FFPE based Wilms' Tumor samples through copy number and somatic mutation related Molecular Inversion Probe Based Array. , 2015, Gene.

[2]  Jayasha Shandilya,et al.  A role of WT1 in cell division and genomic stability , 2015, Cell cycle.

[3]  M. Akhtar,et al.  Wilms Tumor: An Update , 2014, Advances in anatomic pathology.

[4]  Hao Zhu,et al.  Lin28 sustains early renal progenitors and induces Wilms tumor , 2014, Genes & development.

[5]  H. Seuánez,et al.  Association of TP53 polymorphisms on the risk of Wilms tumor , 2014, Pediatric blood & cancer.

[6]  A. Iafrate,et al.  Inactivation of the tumor suppressor WTX in a subset of pediatric tumors , 2014, Genes, chromosomes & cancer.

[7]  H. Seuánez,et al.  WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor. , 2013, Oncology reports.

[8]  M. Rivera,et al.  The WTX tumor suppressor enhances p53 acetylation by CBP/p300. , 2012, Molecular cell.

[9]  Nazneen Rahman,et al.  Stratification of Wilms tumor by genetic and epigenetic analysis , 2012, Oncotarget.

[10]  Keith L. Ligon,et al.  Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples , 2009, PloS one.

[11]  M. Rivera,et al.  The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity , 2009, Proceedings of the National Academy of Sciences.

[12]  M. Cubellis,et al.  Inherited and Sporadic Epimutations at the IGF2-H19 locus in Beckwith-Wiedemann syndrome and Wilms' tumor. , 2009, Endocrine development.

[13]  C. Thaller,et al.  Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis , 2009, Nature Genetics.

[14]  V. Huff,et al.  Wilms tumor genetics: Mutations in WT1, WTX, and CTNNB1 account for only about one‐third of tumors , 2008, Genes, chromosomes & cancer.

[15]  Anne-Claude Gingras,et al.  Wilms Tumor Suppressor WTX Negatively Regulates WNT/ß-Catenin Signaling , 2007, Science.

[16]  V. Huff Wilms tumor genetics: a new, UnX-pected twist to the story. , 2007, Cancer cell.

[17]  A. Feinberg,et al.  An X Chromosome Gene, WTX, Is Commonly Inactivated in Wilms Tumor , 2007, Science.

[18]  M. von Knebel Doeberitz,et al.  Nuclear accumulation of β‐catenin protein in Wilms' tumours † , 2003 .

[19]  C. Amos,et al.  Frequent Association of β-Catenin and WT1 Mutations in Wilms Tumors , 2000 .

[20]  A. Knudson,et al.  Mutation and cancer: a model for Wilms' tumor of the kidney. , 1972, Journal of the National Cancer Institute.